Actuate Therapeutics, Inc. Operating Lease, Expense
Actuate Therapeutics, Inc. (ACTU) reported Operating Lease, Expense of $13.10 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-14
- Actuate Therapeutics, Inc. operating lease, expense for the quarter ending 2026-06-30 was $13.10K, a 2.34% increase year-over-year.
- Actuate Therapeutics, Inc. operating lease, expense for the quarter ending 2026-03-31 was $12.90K, a 0.78% increase year-over-year.
- Actuate Therapeutics, Inc. operating lease, expense for the quarter ending 2025-12-31 was $12.90K.
- Actuate Therapeutics, Inc. operating lease, expense for the quarter ending 2025-09-30 was $12.90K.
- Actuate Therapeutics, Inc. operating lease, expense for fiscal 2025 was $51.20K, a 1119.05% increase from fiscal 2024.
- Actuate Therapeutics, Inc. operating lease, expense for fiscal 2024 was $4.20K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $13.10K 10-Q · filed 2026-08-14 | $26.00K 10-Q · filed 2026-08-14 | $38.90K derived: sum of 3 quarters · filed 2026-08-14 | $51.80K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $12.90K 10-Q · filed 2026-05-14 | $25.80K derived: sum of 2 quarters · filed 2026-05-14 | $38.70K derived: sum of 3 quarters · filed 2026-05-14 | $51.50K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2025-12-31 | $12.90K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $25.80K derived: sum of 2 quarters · filed 2026-03-26 | $38.60K derived: sum of 3 quarters · filed 2026-03-26 | $51.20K 10-K · filed 2026-03-26 | |
| 2025-09-30 | $12.90K 10-Q · filed 2025-11-13 | $25.70K derived: sum of 2 quarters · filed 2025-11-13 | $38.30K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $12.80K 10-Q · filed 2025-08-14 | $25.40K 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | $12.80K 10-Q · filed 2026-08-14 | $12.60K 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $4.20K 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |